OBJECTIVE: To evaluate the operating properties of endomysial antibodies (EMAs) in the diagnosis of @entity1593 and to examine, using a cost minimization model, different strategies used in the diagnosis of @entity1593 . METHODS: A total of 248 @entity10208 results were reviewed and compared with small bowel biopsy results in 66 @entity1 who had undergone both tests. Regression analysis was used to look for predictors of positive @entity10208 results and positive biopsy results. A cost minimization model from a societal perspective was used to evaluate the cost differences among three different strategies. RESULTS: EMAs had a sensitivity of 95% and specificity of 64%. The only predictor of a positive biopsy result that reached statistical significance was a positive @entity10208 . The strategy of @entity10208 as a diagnostic test for @entity1593 was the most expensive strategy, with a cost of  3,174 per @entity1 assessed. The strategy of small bowel biopsy for all @entity1 had a cost of  997, and a strategy of @entity10208 followed by small bowel biopsy for positive @entity1 had a cost of  866 per @entity1 . The results were sensitive to cost of a gluten-free diet, the specificity of the @entity10208 and the cost of a small bowel biopsy. CONCLUSION: The @entity10208 is best used as a screening test from both a clinical and cost perspective.

Evaluation of the endomysial antibody for XXXX : operating properties and associated cost implications in clinical practice.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity10208 :: ('MESH:D054069', 'Disease') :: ['EMA'] @entity1593 :: ('MESH:D002446', 'Disease') :: ['celiac disease']
@entity1593 :: (MESH:D002446,Disease) :: ['celiac disease']
